Cervical Cancer Screening Market Growth Is Attributed To The Increasing Awareness And Technological Advancements

According to Precision Business Insights (PBI) latest report the Cervical Cancer Screening Market size was valued at USD 445.5 million in 2023 and is expected to grow at USD 463.3 million in 2030 to grow at a CAGR of 2.3% during the forecast period 2024-2030. Cervical cancer is the fourth most common cancer in women globally with around 6,60,000 new cases and around 3,50,000 deaths in 2022. Technological innovations are significantly driving the cervical cancer screening market forward. Traditional pap smears are being supplemented or replaced by more advanced techniques for instance, liquid-based cytology, and HPV DNA testing, improving both the accuracy of screening and patient experience Additionally, Public health campaigns and education initiatives are playing a crucial role in raising awareness about the importance of regular screening, due to which in US Screening coverage (35-69 Yrs.) women raised to 73.13% in 2023. This increased awareness is leading to higher screening rates and earlier detection of cervical abnormalities.

View The Detailed Report Description Here - https://www.precisionbusinessinsights.com/market-reports/cervical-cancer-screening-market

In Test Type Segment, Pap Smear Test is dominating the Cervical Cancer Screening Market
Based on the Type of Test, while Pap smear tests currently dominate cervical cancer screening with 7,24,27,195 tests in 2023, projections indicate a shift in the coming years. Human Papillomavirus (HPV) tests and liquid-based cytology (LBC) are anticipated to show a significant growth rate in the market share over the forecasting period owing to Improved accuracy and sensitivity and extended screening intervals. In June 2022, Roche introduced a self-sampling tool for HPV testing, marking a significant advancement in cervical cancer screening. This innovation allows women to collect their samples at home or in a healthcare setting, increasing accessibility and convenience. The tool aims to improve screening rates by offering an alternative to traditional methods, which some women may find uncomfortable or inconvenient. By enabling early detection of HPV, a major cause of cervical cancer, this self-sampling option has the potential to contribute to better prevention and treatment outcomes in women's health.

North America Leads Cervical Cancer Screening Market:
Cervical Cancer Screening market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the market holding and is expected to retain its dominance in forecasted years owing to Increased awareness leads to increased Screening (HPV & Pap smears) and Vaccination. For instance, in 2023, 7,23,89,974 tests were done for Cervical cancer. Additionally, favorable changes in the healthcare policy that improve insurance coverage and make care more accessible to the larger population. Europe is likely to grow at a significant CAGR, due to large pool of aging population, better adoption of HPV testing, government initiatives, and Increased awareness.

Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=55008

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
Cervical Cancer Screening market further reveals that the key players increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance,

In Jun 2022, Roche launched a human papillomavirus (HPV) self-sampling tool, expanding cervical cancer screening choices.
• The tool allows individuals to collect their samples for human papillomavirus (HPV) testing. HPV is the primary cause of cervical cancer.
• Self-sampling tool increases accessibility by making it easier for people to get screened, especially those who face barriers to traditional clinical exams.

In April 2024, QIAGEN N.V., a biotechnology company, launched various novel products:
• QIAcuity dPCR PanCancer Kits: These kits uses digital PCR (dPCR) technology and, designed to study multiple types of cancer.
• QIAseq Targeted RNA-seq Panel for T-cell receptors: This panel uses RNA sequencing technology.
• PAXgene Urine Liquid Biopsy Set: It facilitate urine collection and stabilization as a novel liquid biopsy technique and to further advance cancer research.

Request Methodology: https://www.precisionbusinessinsights.com/request-methodology/?product_id=55008

Detailed Segmentation
The Cervical Cancer Screening market is segmented based on Mode of Delivery, Distribution, end user, and geography.
Based on the Test Type, the market is segmented into the following:
• Pap Smear Tests
• HPV Tests
• LBC Tests
• Others

Based on Geography, the market is segmented into the following:
• North America
• Europe
• Asia Pacific
• Latin America
• MEA

Key player's profiles in the Cervical Cancer Screening Market report Hologic Inc., Cepheid Inc., Abbott Laboratories, Becton, Dickinson, Qiagen NV, Access Bio, Inc., Greiner Bio-one, Rovers Medical Device, TruScreen, Hoffmann-La Roche, BioMerieux are a few companies operating in Cervical Cancer Screening market.

Contact:
Mr. Satya
Precision Business Insights | Toll-Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Website: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.